JPMorgan Chase & Co. Purchases 30,735 Shares of Kodiak Sciences Inc. (NASDAQ:KOD)

JPMorgan Chase & Co. lifted its stake in Kodiak Sciences Inc. (NASDAQ:KOD) by 220.9% during the 3rd quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The firm owned 44,648 shares of the company’s stock after buying an additional 30,735 shares during the period. JPMorgan Chase & Co. owned approximately 0.08% of Kodiak Sciences worth $117,000 as of its most recent SEC filing.

A number of other hedge funds and other institutional investors also recently added to or reduced their stakes in the company. State Street Corp lifted its position in Kodiak Sciences by 1.8% during the third quarter. State Street Corp now owns 816,634 shares of the company’s stock valued at $2,131,000 after buying an additional 14,711 shares during the period. Geode Capital Management LLC increased its holdings in shares of Kodiak Sciences by 1.7% during the third quarter. Geode Capital Management LLC now owns 768,740 shares of the company’s stock valued at $2,007,000 after acquiring an additional 12,783 shares in the last quarter. GSA Capital Partners LLP purchased a new position in Kodiak Sciences in the third quarter worth about $751,000. FMR LLC lifted its stake in shares of Kodiak Sciences by 26.4% in the third quarter. FMR LLC now owns 200,971 shares of the company’s stock worth $525,000 after buying an additional 41,987 shares in the last quarter. Finally, Marshall Wace LLP increased its position in shares of Kodiak Sciences by 41.6% during the second quarter. Marshall Wace LLP now owns 166,425 shares of the company’s stock valued at $391,000 after acquiring an additional 48,930 shares in the last quarter. 89.06% of the stock is currently owned by institutional investors.

Analyst Upgrades and Downgrades

Several research analysts have issued reports on the company. HC Wainwright reissued a “neutral” rating and issued a $3.00 target price on shares of Kodiak Sciences in a research report on Friday, November 15th. Barclays lifted their price objective on Kodiak Sciences from $3.00 to $4.00 and gave the company an “underweight” rating in a research report on Friday, November 15th. Finally, Jefferies Financial Group raised Kodiak Sciences from a “hold” rating to a “buy” rating and set a $20.00 price target on the stock in a report on Monday, December 9th.

Kodiak Sciences Stock Performance

Kodiak Sciences stock opened at $6.40 on Monday. The company has a 50 day moving average price of $8.30 and a 200-day moving average price of $5.00. Kodiak Sciences Inc. has a fifty-two week low of $2.18 and a fifty-two week high of $11.60. The company has a market capitalization of $336.77 million, a PE ratio of -1.75 and a beta of 2.11.

Kodiak Sciences Company Profile

Kodiak Sciences Inc, a clinical stage biopharmaceutical company, researches, develops, and commercializes therapeutics to treat retinal diseases. Its lead product candidate is tarcocimab tedromer (KSI-301), an anti-vascular endothelial growth factor antibody biopolymer that is in Phase IIb/III clinical study to treat wet age-related macular degeneration (AMD), as well as Phase III clinical study for the treatment of diabetic macular edema, naïve macular edema due to retinal vein occlusion, and non-proliferative diabetic retinopathy.